In male Wistar rats, oral Silodosin plus phenylephrine inhibited parotid AQP5 trafficking to the APM and LPM compared with saline plus phenylephrine. In male SD rats with BPH, oral Silodosin significantly reduced urinary frequency and increased mean voided volume in a dose-dependent manner compared with vehicle control, with a minimal effective dose of 1 mg/kg. [2,3]
Silodosin Plus Phenylephrine and Parotid AQP5 Trafficking
Animal study · Eight-week-old male Wistar rats [2]
Male Wistar rats received oral Silodosin at 1 mg/kg once daily for 1 week. Silodosin plus phenylephrine inhibited AQP5 trafficking to the APM and LPM in rat parotid tissue, compared with saline plus phenylephrine.
Conditions shared by the study groups
- Route
- oral administration
- Treatment course
- once daily for 1 week
- Silodosin 1 mg/kg
- Model: Eight-week-old male Wistar rats
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Silodosin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S30, S33, S37); 4. Materials and Methods > 4.2. Animals (S84); 4. Materials and Methods > 4.3. Immunohistochemistry (S89, S92, S93, S94); Figure 4 legend (S146, S147)
phenylephrine-induced translocation of AQP5 to the APM and LPM: phenylephrine-induced translocation of AQP5 to the APM and LPM; comparator: saline plus phenylephrine — 2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S30, S33)
Silodosin 1 mg/kg · 2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S33); 4. Materials and Methods > 4.3. Immunohistochemistry (S89); Figure 4 legend (S146)
Silodosin and Voiding Outcomes in BPH Rats
Animal study · Male SD rats (200–250 g) [3]
Male SD rats with BPH received oral Silodosin. Compared with vehicle control, Silodosin significantly reduced urinary frequency and increased mean voided volume in a dose-dependent manner, with a minimal effective dose of 1 mg/kg.
Conditions shared by the study groups
- Route
- oral administration
- Treatment course
- Two days after a lower-dose testing, animals were used for the next higher-dose testing.
- Vehicle
- 0.5% carboxymethyl cellulose sodium
- Silodosin 0.3, 1, 3, and 10 mg/kg
- Model: Male SD rats (200–250 g)
Methods and source locations
Compound reported in the paper: Silodosin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S5); Materials and methods > Micturition recording (S25, S26, S27, S28, S29); Results > Testosterone propionate induces BPH in rats (S39, S40); Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48); Fig 2 legend (S72)
Micturition frequency: Micturition frequency; comparator: vehicle control — Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48); Fig 2 legend (S72)
Silodosin 0.3, 1, 3, and 10 mg/kg · Materials and methods > Micturition recording (S26, S27, S28); Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48)